Minerva Neurosciences Inc
Research Minerva Neurosciences Inc (NERV) on Bullrun: market cap USD 236.14M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNERV
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 236.14M
- Financial periodQ2 2026
- RevenueUSD 0
- Net incomeUSD 17.47M
- Free cash flow-USD 13.34M
Valuation Snapshot
latest market cap is USD 236.14M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 293.42M | -USD 13.51M | n/a | -34.67 | USD 82.30M | n/a | -USD 140.75M |
| FY2024 | USD 0 | USD 1.44M | -USD 19.55M | n/a | 0.19 | USD 21.36M | n/a | -USD 25.69M |
| FY2023 | USD 0 | -USD 30.01M | n/a | n/a | -4.61 | USD 40.91M | n/a | -USD 28.46M |
| FY2022 | USD 0 | -USD 32.11M | -USD 24.66M | n/a | -6.01 | USD 36.09M | n/a | -USD 20.02M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 236.14M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 173.96M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 15.53M | 11.7 | n/a | n/a |
| 2023 | 2023-12-29 | USD 43.01M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 8.49M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 34.23M | n/a | n/a | n/a |
About Minerva Neurosciences Inc
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Minerva Neurosciences Inc's market cap?
Minerva Neurosciences Inc's market capitalization is USD 236.14M.
What does Minerva Neurosciences Inc do?
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.